Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb 21;82(6):1239–1245. doi: 10.1054/bjoc.1999.1069

Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression

F A Scholl 1, D R Betts 2, F K Niggli 2, B W Schäfer 1
PMCID: PMC2363357  PMID: 10735512

Abstract

A novel human cell line was established from a primary botryoid rhabdomyosarcoma. Reverse transcription polymerase chain reaction investigations of this cell line, called RUCH-2, demonstrated expression of the regulatory factors PAX3, Myf3 and Myf5. After 3.5 months in culture, cells underwent a crisis after which Myf3 and Myf5 could no longer be detected, whereas PAX3 expression remained constant over the entire period. Karyotype analysis revealed breakpoints in regions similar to previously described alterations in primary rhabdomyosarcoma tumour samples. Interestingly, cells progressed to a metastatic phenotype, as observed by enhanced invasiveness in vitro and tumour growth in nude mice in vivo. On the molecular level, microarray analysis before and after progression identified extensive changes in the composition of the extracellular matrix. As expected, down-regulation of tissue inhibitors of metalloproteinases and up-regulation of matrix metalloproteinases were observed. Extensive down-regulation of several death receptors of the tumour necrosis factor family suggests that these cells might have an altered response to appropriate apoptotic stimuli. The RUCH-2 cell line represents a cellular model to study multistep tumorigenesis in human rhabdomyosarcoma, allowing molecular comparison of tumorigenic versus metastatic cancer cells. © 2000 Cancer Research Campaign

Keywords: rhabdomyosarcoma, myogenic transcription factors, PAX, metastasis, cytogenetic alteration

Full Text

The Full Text of this article is available as a PDF (158.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anand G., Shapiro D. N., Dickman P. S., Prochownik E. V. Rhabdomyosarcomas do not contain mutations in the DNA binding domains of myogenic transcription factors. J Clin Invest. 1994 Jan;93(1):5–9. doi: 10.1172/JCI116982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997 Jul 3;72(1):1–22. doi: 10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  3. Apte S. S., Fukai N., Beier D. R., Olsen B. R. The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis. J Biol Chem. 1997 Oct 10;272(41):25511–25517. doi: 10.1074/jbc.272.41.25511. [DOI] [PubMed] [Google Scholar]
  4. Barr F. G., Galili N., Holick J., Biegel J. A., Rovera G., Emanuel B. S. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993 Feb;3(2):113–117. doi: 10.1038/ng0293-113. [DOI] [PubMed] [Google Scholar]
  5. Barr F. G., Nauta L. E., Hollows J. C. Structural analysis of PAX3 genomic rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet. 1998 Apr 1;102(1):32–39. doi: 10.1016/s0165-4608(97)00287-2. [DOI] [PubMed] [Google Scholar]
  6. Betts D. R., Koesters R., Plüss H. J., Niggli F. K. Routine karyotyping in Wilms tumor. Cancer Genet Cytogenet. 1997 Jul 15;96(2):151–156. doi: 10.1016/s0165-4608(96)00318-4. [DOI] [PubMed] [Google Scholar]
  7. Clark J., Rocques P. J., Braun T., Bober E., Arnold H. H., Fisher C., Fletcher C., Brown K., Gusterson B. A., Carter R. L. Expression of members of the myf gene family in human rhabdomyosarcomas. Br J Cancer. 1991 Dec;64(6):1039–1042. doi: 10.1038/bjc.1991.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Davis R. J., D'Cruz C. M., Lovell M. A., Biegel J. A., Barr F. G. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994 Jun 1;54(11):2869–2872. [PubMed] [Google Scholar]
  9. Galili N., Davis R. J., Fredericks W. J., Mukhopadhyay S., Rauscher F. J., 3rd, Emanuel B. S., Rovera G., Barr F. G. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993 Nov;5(3):230–235. doi: 10.1038/ng1193-230. [DOI] [PubMed] [Google Scholar]
  10. Glinsky G. V., Glinsky V. V., Ivanova A. B., Hueser C. J. Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett. 1997 May 19;115(2):185–193. doi: 10.1016/s0304-3835(97)04738-1. [DOI] [PubMed] [Google Scholar]
  11. Kullendorff C. M., Donner M., Mertens F., Mandahl N. Chromosomal aberrations in a consecutive series of childhood rhabdomyosarcoma. Med Pediatr Oncol. 1998 Mar;30(3):156–159. doi: 10.1002/(sici)1096-911x(199803)30:3<156::aid-mpo5>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  12. Ludolph D. C., Konieczny S. F. Transcription factor families: muscling in on the myogenic program. FASEB J. 1995 Dec;9(15):1595–1604. doi: 10.1096/fasebj.9.15.8529839. [DOI] [PubMed] [Google Scholar]
  13. McAllister R. M., Melnyk J., Finkelstein J. Z., Adams E. C., Jr, Gardner M. B. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer. 1969 Sep;24(3):520–526. doi: 10.1002/1097-0142(196909)24:3<520::aid-cncr2820240313>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  14. Nanni P., Schiaffino S., De Giovanni C., Nicoletti G., Prodi G., Del Re B., Eusebi V., Ceccarelli C., Saggin L., Lollini P. L. RMZ: a new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin. Br J Cancer. 1986 Dec;54(6):1009–1014. doi: 10.1038/bjc.1986.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Newton W. A., Jr, Gehan E. A., Webber B. L., Marsden H. B., van Unnik A. J., Hamoudi A. B., Tsokos M. G., Shimada H., Harms D., Schmidt D. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study. Cancer. 1995 Sep 15;76(6):1073–1085. doi: 10.1002/1097-0142(19950915)76:6<1073::aid-cncr2820760624>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  16. Pappo A. S. Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr Opin Oncol. 1995 Jul;7(4):361–366. doi: 10.1097/00001622-199507000-00012. [DOI] [PubMed] [Google Scholar]
  17. Schäfer B. W., Czerny T., Bernasconi M., Genini M., Busslinger M. Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes. Nucleic Acids Res. 1994 Nov 11;22(22):4574–4582. doi: 10.1093/nar/22.22.4574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Scrable H. J., Witte D. P., Lampkin B. C., Cavenee W. K. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature. 1987 Oct 15;329(6140):645–647. doi: 10.1038/329645a0. [DOI] [PubMed] [Google Scholar]
  19. Shapiro D. N., Sublett J. E., Li B., Downing J. R., Naeve C. W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 1993 Nov 1;53(21):5108–5112. [PubMed] [Google Scholar]
  20. Takaoka A., Adachi M., Okuda H., Sato S., Yawata A., Hinoda Y., Takayama S., Reed J. C., Imai K. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene. 1997 Jun 19;14(24):2971–2977. doi: 10.1038/sj.onc.1201147. [DOI] [PubMed] [Google Scholar]
  21. Tonin P. N., Scrable H., Shimada H., Cavenee W. K. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res. 1991 Oct 1;51(19):5100–5106. [PubMed] [Google Scholar]
  22. Tran T. A., Kallakury B. V., Ambros R. A., Ross J. S. Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma. Cancer. 1998 Jul 15;83(2):276–282. [PubMed] [Google Scholar]
  23. Wang-Wuu S., Soukup S., Ballard E., Gotwals B., Lampkin B. Chromosomal analysis of sixteen human rhabdomyosarcomas. Cancer Res. 1988 Feb 15;48(4):983–987. [PubMed] [Google Scholar]
  24. Weber-Hall S., Anderson J., McManus A., Abe S., Nojima T., Pinkerton R., Pritchard-Jones K., Shipley J. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res. 1996 Jul 15;56(14):3220–3224. [PubMed] [Google Scholar]
  25. Whang-Peng J., Knutsen T., Theil K., Horowitz M. E., Triche T. Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer. 1992 Nov;5(4):299–310. doi: 10.1002/gcc.2870050405. [DOI] [PubMed] [Google Scholar]
  26. Wyllie A. H. Apoptosis and carcinogenesis. Eur J Cell Biol. 1997 Jul;73(3):189–197. [PubMed] [Google Scholar]
  27. van den Oord J. J., Paemen L., Opdenakker G., de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol. 1997 Sep;151(3):665–670. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES